glp-1/gip dual agonist lilly Diabetes Patients Also Struggle to Access GLP-1 Agonists Eli Lilly and phase results

Source: Segal SHAPE, Segals data warehouse, 2018 to 2022 Weight loss continues to be an important topic for many Americans

van Ruiten CC, Smits MM, Kok MD, et al

If you're searching for a true GLP-1 medication alternative that produces comparable clinical results, you need to work with a healthcare provider who can evaluate whether prescription options are appropriate for your situation

While injectable GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment landscape for obesity and type 2 diabetes, their reliance on subcutaneous injection remains a significant barrier to broader adoption

Author contribution Conceptualization: BJ, MM, RK, RJ

Additionally, no dose-response relationship was observed within the studied dosage range for the other six GLP-1RA drugs, such as Liraglutide (1.23 mg), where no significant change in weight reduction effect was noted within this range, indicating that the dosages of these drugs have reached their efficacy plateaus